Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Alessandra Tucci, MD, Alessandro Re, MD, Chiara Pagani, MD, Anna Guidetti, Anna Dodero, Fabrizio Marino, MD, Ivana Casaroli, MD, Giulia Soverini, MD, Rosa Daffini, MD, Monica Balzarotti, Giulia Campostrini, Luisa Lorenzi, MD, Piera Balzarini, Fabio Facchetti, Carmelo Carlo-Stella, MD, Paolo Corradini, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139977

Published: 2020

Journal Articles

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134875

Published: 2020

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Chiara Pagani, MD, Monica Fumagalli, MD, Patrizia Zappasodi, MD, Erika Borlenghi, MD, Alessandro Re, MD, Fabio Ciceri, MD, Margherita Sciumé, Roberto Cairoli, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 3603.

https://doi.org/10.1182/blood-2019-125288

Published: 2019

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study

Blood (2018) 132 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2018-99-116437

Published: 2018

Journal Articles

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Nicola Bianchetti, Alessandra Tucci, Alessandro Re, MD, Chiara Pagani, MD, Chiara Cattaneo, MD, Maria Miscio, Fabio Facchetti, Simona Fisogni, MD, Piera Balzarini, Domenico Albano, Giovanni Bosio, Francesco Bertagna, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2018-99-119090

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Alessandro Re, MD, Nicola Bianchetti, Chiara Cattaneo, MD, Salvatore Casari, MD, Chiara Pagani, MD, Annalisa Peli, MD, Emanuele Focà, MD, Pierino ferremi Leali, MD, Camillo Almici, MD, Francesco Castelli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2018-99-116816

Published: 2018

Journal Articles

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

Blood (2018) 132 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2018-99-116060

Published: 2018

Journal Articles

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Annalisa Chiappella, MD, Cristiana Carniti, Andrea Evangelista, PhD, Maria Giuseppina Cabras, MD, Alessandro Re, MD, Manuela Zanni, MD, Vittorio Stefoni, Armando Santoro, MD, Angela Giovanna Congiu, Anna Dodero, MD, Stefano A. Pileri, MD PhD, Giovannino Ciccone, MD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2018-99-119763

Published: 2018

Journal Articles

A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or with Primary Refractory Disease — FIL_BVHD01

Lorenzo Tonialini, MD, Vittorio Stefoni, Alessandro Re, MD, Arben Lleshi, MD, Maurizio Bonfichi, MD, Antonello Pinto, Nicola Bianchetti, Lisa Argnani, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 2920.

https://doi.org/10.1182/blood-2018-99-111812

Published: 2018

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Alessandra Tucci, MD, Anna Guidetti, MD, Anna Dodero, MD, Francesca Schieppati, MD, Alessandro Re, MD, Nicola Bianchetti, MD, Chiara Bottelli, MD, Angela Passi, MD, Maria Miscio, Simona Fisogni, MD, Piera Balzarini, Fabio Facchetti, MD, Paolo Corradini, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4154.

https://doi.org/10.1182/blood.V130.Suppl_1.4154.4154

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Blood (2017) 130 (Supplement 1): 4072.

https://doi.org/10.1182/blood.V130.Suppl_1.4072.4072

Published: 2017

Journal Articles

Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial

Andrés J M Ferreri, MD, Michele Spina, Chiara Cattaneo, MD, Luisa Verga, MD, Bernardino Allione, Daris Ferrari, Luigi Rigacci, Luca Fumagalli, MD, Giovanni Donadoni, MD, Arben Lleshi, MD, Marianna Sassone, MD, Giuseppe Rossi, MD, Alessandro Re, MD

Blood (2017) 130 (Supplement 1): 2828.

https://doi.org/10.1182/blood.V130.Suppl_1.2828.2828

Published: 2017

Journal Articles

Aids Related Primary Central Nervous System Lymphoma Is Still a Challenge in the Cart Era: A Single Centre Experience

Alessandro Re, MD, Chiara Cattaneo, MD, Salvatore Casari, MD, Annalisa Peli, MD, Nicola Bianchetti, MD, Angela Passi, MD, Emanuele Focà, MD, Maria Miscio, Francesco Castelli, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 5223.

https://doi.org/10.1182/blood.V130.Suppl_1.5223.5223

Published: 2017

Journal Articles

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

Chiara Cattaneo, MD, Doriana Gramegna, Chiara Pagani, MD, Erika Borlenghi, Michele Malagola, MD, Elisa Cerqui, MD, Angela Passi, MD, Francesca Schieppati, MD, Claudia Crippa, MD, Daniela Dalceggio, Cecilia Carbone, MD, Anna Maria Pelizzari, Margherita Sciumé, Alessandro Re, MD, Domenico Russo, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 2288.

https://doi.org/10.1182/blood.V130.Suppl_1.2288.2288

Published: 2017

Journal Articles

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Vittorio Stefoni, Beatrice Casadei, MD, Barbara Botto, Paolo Corradini, MD, Antonello Pinto, Alessandro Re, MD, Stefania Badiali, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4087.

https://doi.org/10.1182/blood.V130.Suppl_1.4087.4087

Published: 2017

Journal Articles

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party

Kai Huebel, MD, Alessandro Re, MD, Ariane Boumendil, PhD, Herve Finel, Marcus Hentrich, Mariagrazia Michieli, Edward Kanfer, Jose Luis Diez-Martin, MD PhD, Pascual Balsalobre, Laure Vincent, Wilfried Schroyens, MD PhD, Josep Maria Ribera Santasusana, Nicolaus Kröger, MD, Xaver Schiel, MD, Kirsty J Thomson, MD, Jorge Sierra, MD, Aida Botelho Sousa, Silvia Montoto, MD, Peter Dreger, MD

Blood (2016) 128 (22): 2257.

https://doi.org/10.1182/blood.V128.22.2257.2257

Published: 2016

NARROW

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or with Primary Refractory Disease — FIL_BVHD01

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial

Aids Related Primary Central Nervous System Lymphoma Is Still a Challenge in the Cart Era: A Single Centre Experience

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only